
The company is a company founded by Chinese and British scientists, focusing on the research and development and application of cell and gene therapy drugs, with "reprogramming technology" as the core. The company's core R&D team comes from Peking University, Cambridge University, Aston University, the UK Sanger Institute and other universities and research institutions, and is committed to converting regenerative medicine research into industrialized cell drugs, and applying the world's leading pluripotent stem cell induction and differentiation technology to the clinic. The company is based…
Built from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Annual Revenue$50M to $100M
Estimated OwnershipPrivateMatching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.